EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Kyverna Therapeutics's enterprise value is $-26.10 Mil.
Kyverna Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-46.33 Mil. Therefore, Kyverna Therapeutics's EV-to-EBITDA for today is 0.56.
The historical rank and industry rank for Kyverna Therapeutics's EV-to-EBITDA or its related term are showing as below:
KYTX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -37.74 Med: -24.16 Max: 0.56
Current: 0.56
During the past 3 years, the highest EV-to-EBITDA of Kyverna Therapeutics was 0.56. The lowest was -37.74. And the median was -24.16.
KYTX's EV-to-EBITDA is ranked better than 85.71% of 462
companies
in the Biotechnology industry
Industry Median: 8.545
vs KYTX: 0.56
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Kyverna Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Kyverna Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Kyverna Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Kyverna Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyverna Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kyverna Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Kyverna Therapeutics's EV-to-EBITDA falls into.
Kyverna Therapeutics's current Enterprise Value is $-26.10 Mil.
Kyverna Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-46.33 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Kyverna Therapeutics's PE Ratio for today is calculated as:
Kyverna Therapeutics's share price for today is $7.72.
Kyverna Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.626.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Kyverna Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Kyverna Therapeutics (Kyverna Therapeutics) Business Description
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KYTX has been successfully added to your